Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4872258
Max Phase: Preclinical
Molecular Formula: C36H41N7O6S
Molecular Weight: 699.83
Molecule Type: Unknown
Associated Items:
ID: ALA4872258
Max Phase: Preclinical
Molecular Formula: C36H41N7O6S
Molecular Weight: 699.83
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C[C@H](NC(=O)N1CCC(NC(=O)c2nccs2)CC1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)[C@@]1(C)CO1
Standard InChI: InChI=1S/C36H41N7O6S/c1-22(39-35(48)43-15-12-25(13-16-43)40-33(47)34-37-14-17-50-34)31(45)42-29(19-24-20-38-27-11-7-6-10-26(24)27)32(46)41-28(30(44)36(2)21-49-36)18-23-8-4-3-5-9-23/h3-11,14,17,20,22,25,28-29,38H,12-13,15-16,18-19,21H2,1-2H3,(H,39,48)(H,40,47)(H,41,46)(H,42,45)/t22-,28-,29-,36+/m0/s1
Standard InChI Key: DFINWNNMGCBCLX-BGCNNDQISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 699.83 | Molecular Weight (Monoisotopic): 699.2839 | AlogP: 2.73 | #Rotatable Bonds: 13 |
Polar Surface Area: 177.92 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 5 |
#RO5 Violations: 1 | HBA (Lipinski): 13 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.96 | CX Basic pKa: | CX LogP: 2.24 | CX LogD: 2.24 |
Aromatic Rings: 4 | Heavy Atoms: 50 | QED Weighted: 0.13 | Np Likeness Score: -0.52 |
1. Li X, Hong D, Zhang M, Xu L, Zhou Y, Li J, Liu T.. (2021) Development of peptide epoxyketones as selective immunoproteasome inhibitors., 221 [PMID:34087498] [10.1016/j.ejmech.2021.113556] |
Source(1):